Evaluation of Immunohistochemical Reactivity with Avidin-Biotin Complex (ABC) Method

Evaluation of Immunohistochemical Reactivity with Avidin-Biotin Complex (ABC) Method

Main Article Content

C. Sandoval
B. Vásquez

Abstract

Immunohistochemistry is any technique that can detect cellular and extracellular components in situ by means of specific antibodies, using enzymatic detection systems. Among immunohistochemical methods, the technique of avidin - biotin complex (ABC) is widely used because of its high sensitivity. The aim of this study was to evaluate the immunohistochemical reactivity of the 4C4.9 antibody for detection of S-100 protein using the ABC method. For the evaluation of immunohistochemical reactivity 2 biopsies of human skin were used with histopathological diagnosis of ulcerated malignant melanoma and melanocytic intradermal nevi from the Research Laboratory on Animal Biotechnology of the Universidad de La Frontera, Chile. The Kit VECTASTAIN® was used as detection method, the dilution the 4C4.9 antibody was 1/250 and incubation temperature was at 4 ° C or 37 °C for 18 hours. To validate the technique, a positive control and a negative for 4C4.9 was performed. The results of immunohistochemical staining by the method of ABC complex showed positive staining for protein S-100 both in ulcerated malignant melanoma and melanocytic intradermal nevi, incubated for 18 hours at 4 ° C or 37 ° C. However, immunostaining was more intense when the primary antibody was incubated at 37° C. For a correct interpretation of the results, it is necessary to take into consideration that the antigen-antibody reaction is influenced by various factors such as the concentration of antibody, time and temperature of incubation. In conclusion, our results suggest incubating the samples with the first antibody (4C4.9) at 1/250 dilution in distilled water, incubating for 18 h at 37 oC. However, immunostaining was more intense when the primary antibody was incubated at 37° C. For a correct interpretation of the results, it is necessary to take into consideration that antigen- antibody reaction is influenced by various factors such as the concentration of antibody, time and temperature of incubation. In conclusion, our results suggest incubating the samples with the first antibody (4C4.9) at 1/250 dilution in distilled water, incubating for 18 h at 37 oC. The use of the antibody 4C4.9 is recommended to support the diagnosis and differential diagnosis.

References

Avrameas, S. & Uriel, J. Méthode de marquage d’antigènes et d’anticorps avec des enzymes et son application en immunodiffusion. C R Hebd. Séans Acad. Sci. Paris, 262:2543-5, 1966.

Barrionuevo, C.; Seminar, V.; Maita, R.; Rosas, R.; Jara, D.; Victorio, J. & Escalante, I. Inmunohistoquímica en lesions cutáneas melanocíticas: Utilidad de los marcadores antígeno S100, HMB-45, Cromogranina A y Proteína p53. Anal. Fac. Med., 60(4):257-264, 1999.

Blessing, K.; Sanders, D. S. & Grant, J. J. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology, 32(2):139-46, 1998.

Casariego, Z. J. & Baudo, J. E. Trabajo de revisión: melanoma. Av. Periodon. Implantol., 16(3):157- 77, 2004.Cell Marque. Cell Marque Portfolio: S-100 (4C4.9) Mouse Monoclonal. Sigma-Aldrich Co., 2016. Disponible en: http://www.cellmarque.com/ antibodies/CM/138/S-100_4C4-9

Cigüenza, M.; Caba, M.; Castaño, D. M.; Delgado, Y.; Ocón, E. M. & Gómez, N. Metástasis músculoesqueléticas en los pacientes con melanoma. En: 31 Congreso Nacional de la SERAM. Sociedad Española de Radiología Médica, S-0732, 2012. Disponible en: http://dx.doi.org/10.1594/ seram2012/S-0732

de Wit, N. J.; van Muijen, G. N. & Ruiter, D. J.Immunohistochemistry in melanocytic proliferative lesions. Histopathology, 44(6):517-41, 2004.

Doherty, M. J; Russo, G. G.; Jolly, H. W. & Stewart, K. R. Immunoenzyme techniques in dermatopathology. J. Am. Acad. Dermathol., 20(5 Pt 1):827-37, 1989.

Doherty, M. J; Russo, G. G.; Jolly, H. W. & Stewart, K. R. Immunoenzyme techniques in dermatopathology. J. Am. Acad. Dermathol., 20(5 Pt 1):827-37, 1989.

Fuertes, L.; Santonja, C.; Kutzner, H. & Requena, L. Immunohistochemistry in dermatopathology: a review of the most commonly used antibodies (part II). Actas Dermosifiliogr., 104(3):181-203, 2013.

Gaynor, R.; Irie, R.; Morton, D. & Herschan, H. R. S100 protein is present in cultured human malignant melanomas. Nature, 286(5771):400- 1, 1980.

González, S. Neoplasias de la Piel. En: Chuaqui, R.; Duarte, I.; González, S.; Etchart, M. & Rosenberg, H. Lecciones de Anatomía Patológica. Santiago de Chile, Pontificia Universidad Católica de Chile, 2016. Disponible en: http://escuela.med.puc.cl/ publ/anatomiapatologica/10Dermatopatologia/ 10neoplasias.html Hauschild, A. The use of serological tumor markersfor malignant melanoma. Onkologie, 20(6):462-5, 1997.

Kahn, H. J.; Marks, A.; Thom, H. & Baumal, R. Role of antibody to S100 protein in diagnostic pathology. Am. J. Clin. Pathol., 79(3):341-7, 1983.

Luelmo, J. Nevus melanocítico en la infancia. An. Esp. Pediatr., 54(5):477-83, 2001.

Machado, N. P.; Téllez, G. A. & Castaño, J. C. Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas. Infectio., 10(3):186-97, 2006.

Markovic, S. N.; Erickson, L. A.; Rao, R. D.; Weenig, R. H.; Pockaj, B. A.; Bardia, A.; Vachon, C. M.; Schild, S. E.; McWilliams, R. R.; Hand, J. L.; Laman, S. D.; Kottschade, L. A.; Maples, W. J.; Pittelkow, M. R.; Pulido, J. S.; Cameron, J. D.; Creagan, E. T.; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st Century, part 1: epidemiology, risk factors, screening, prevention and diagnosis. Mayo Clinic. Proc., 82(3):364-80, 2007.

Martín-Lacave, I. & García Caballero, T. Atlas de Inmunohistoquímica. Díaz de Santos, Madrid, 2014.

Molina, F. Melanoma Maligno. En: Manual de Oncología Clínica y Molecular. Rosell, R.; Abad, A.; Monzó, M. & Bardanas, A. (ed.) Arán Ediciones, 2000.

Monda, L. & Wick, M. R. S-100 protein immunostaining in the differential diagnosis of chondroblastoma. Hum. Pathol., 16(3):287-93,1985.

Moore, B. W. A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun., 19(6):739-44, 1965.

Morrison, C. D. & Prayson, R. A. Immunohistochemistry in the diagnosis of neoplasms of the central nervous system. Semin. Diagn. Pathol., 17(3):204-15, 2000.

Nakajima, T.; Watanabe, S.; Sato, Y.; Kameya, T.; Hirota, T. & Shimosato, Y. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am. J. Surg. Pathol., 6(8):715- 27, 1982.

Nakane, P. K. & Pierce, G. B. Jr. Enzyme-labeled antibodies: Preparation and application for the localization of antigens. J. Histochem. Cytochem.,14(12):929-31, 1966.

Panizo, A.; Idoate, M. & Sola, I. Glosario de Inmunohistoquímica. Rev. Esp. Patol., 31(2):171- 2, 1998.

Park, H. R. & Min, S. K. Expression of S100A2 and S100B proteins in epithelial tumors of the skin. J. Cutan. Pathol., 30(6):373-8, 2003.

Patel, P.; Levin, K.; Waltz, K. & Helm, K. F. Myxoid melanoma: immunohistochemical studies and a review of the literature. J. Am. Acad. Dermatol., 46(2):264-70, 2002.

Tofani, A.; Cioffi, R. P.; Sciuto, R.; Rea, S.; Festa, A.; Di-Filippo, F.; Cavaliere, R. & Maini, C. L. S100 and NSE as serum markers in melanoma. Acta Oncol., 36(7):761-4, 1997.

Vector Laboratories. VECTASTAIN Universal Quick HRP Kit (Peroxidase), R.T.U. (Ready-to-Use). Catalog Number: PK-7800. Vector Laboratories Inc., 2016. Disponible en: https://vectorlabs.com/vectastainuniversal-quick-kit-r-t-u-ready-to-use.html Weedon, D. Skin Pathology. 2nd ed. London, England: Churchill, Livingstone, 2002.

Yaziji, H. & Gown, A. M. Immunohistochemical markers of melanocytic tumors. Int. J. Surg. Pathol., 11(1):11-5, 2003.